Similar to self vaccination, oncolytic virus therapy also induces tumor antigen release and provides danger signals, which consequently enhances T cell priming and ameliorates anti-PD1/PDL1 resistance (Guo et al., 2014; Long et al., 2016). This evidence concerns the gene PDCD1 and neoplasm.